DURHAM, N.C. — Expression Analysis has landed a contract with GlaxoSmithKline to provide the pharmaceutical giant with microarray-based genotyping services.
Microarray technology enables researchers to genetic information such as gene “expression” or what genes are “turned on”.
Financial terms were not disclosed.
“Expression Analysis has developed the expertise and infrastructure to provide our pharmacogenomic clients with significant value based on our knowledge of microarray-based technology and the dedication of our staff to providing high-quality results,” said Steve McPhail, president and chief executive officer of Expression Analysis. “This agreement advances our goal of supporting pharmacogenomic studies in clinical trials.”
Expression Analysis has built up its infrastructure over the past two years to help pharmaceutical companies in clinical trials of drug candidates.
Expression Analysis: www.expressionanalysis.com